You can question management for several reasons. Recently Cor as a company had us believe they were dispersing their efforts in order to manage their many irons in the fire. It appears just the opposite. Convergence of one molecule targeting new ghost indications. A move necessary to save the company. It instead created a financial predicament that leaves the company in the same position it would have been in had they put their IP up for sale a year or more ago. Not to mention the better share price and lack of dilution that would have been awarded them had they gone that route. This clearly was a calculated risk. Management has taken one blinded solo shot on goal after another yet the promise of many irons in the fire surfaced for no reason. Why say that? A waste of words. In spite of the current economic climate, that statement would have you believe as an investor that Cor management does have a strategic plan and does have other options should their current situation not pan out. Management has made statements of relative untruths which may have been misleading to investors. Regardless of the ADHD debacle, management had me believing that something was indeed just over the horizon, that obviously was not the case. Why take the company down the path of obvious financial drain without guaranteed result in a timely and necessary manner. If they did not know how long an SA trial would take, they ought not have gone there. If they were unsure an RD deal could be inked, why bother with an uncertain BP interest. POC without players is as good as no POC when you are financially vulnerable. Yeah they say they had someone at the table but funds were pulled, whatever. They again are saying they have many suitors for M&A, buyout, etc., and we again will have to take their word. What will thwart their efforts this time, the Korean missile crisis? There is no proof and clearly no result. There should have been plenty of available historical industry data for them to analyze prior to making these critical decisions.
<<ADHD after the good study results--yes, that is a no-brainer. But what was the back-up plan? How much effort was extended to secure prtnshps for other indications? I believe virtually none. Cor has not been able to handle many irons (contrary to Stoll's infamous remarks), nor have they seemed to fire on more than one cylinder--one awful pipe at a time, one molecule at a time, and one indication at a time. While undertaking new studies or multiple indications costs more than they can obviously afford; getting the word out; making appointments with suitors; negotiating favorable deals; in other words: demonstrating skilled business savvy, is included in their salary. >>
In general that statement seems to hold true. Regardless of your position as a bio industry insider or unlucky bio tech message board voyeur, business practices and approaches should remain the same. Clearly bio technology has its own unique set of requirements and hurdles, nonetheless, a CEO needs to be more than just a clever dick when it comes to his or her product, be it molecules or fried chicken. A CEO needs to be well versed and possess an in depth knowledge of the rules, regulatory hurdles, and parameters for success in the arena of which he or she chooses to play. Extensive efforts in marketing, research and development, and sales all play a role in the progression towards success of a product or company. Cor management has obviously failed in some of these categories. As another poster recently stated, there are far worse off small cap bio companies trading at far better market caps with far less in IP value and prospect. Therefore, if that statement holds water, the keepers of the technology must bear the weight of the failures and take the blame for the current share price cast upon their loyal believers and investors. Every business on earth can present a bible of reasons for their company's successes or failures. Share price is a straight forward barometer of these successes or failures, period. And it appears now that the eye of the storm has taken its position over Cal-Irvine. If Cor was trading at $10 a share, I guarantee you top brass would deservedly take the credit. They therefore need to take the blame for our current position and historically low sp. In spite of all this, we as investors need to consider that the resulted mindful misery that comes with a poor investment is near that of a self inflicted gun shot wound. Unintended and stupid in hindsight yet solely your responsibility. I guess in my case, I was blinded by the writing on the wall, albeit in chinese. So bring on the board of interpreters who unfortunately allowed me to believe that I may have accidently wondered upon the bio tech holy grail, amapkines. Every student needs a teacher not the other way around and had this baby turned out I would have certainly offered many thanks. Lesson learned, next time I'll either learn chinese or call Ron Howard to expose the truth. F4T.
